US equities |
NVDA $181.60 ▼-9.26% MU $656.39 ▼-17.46% AMD $404.40 ▼-17.26% TSLA $343.69 ▼-10.77% AAPL $344.17 ▼-1.53% SNDK $806.43 ▼-22.26% MSFT $535.93 ▼-3.58% AMZN $260.21 ▼-2.19%
FinancialContent

Nautilus Biotechnology, Inc. - Common Stock (NQ:NAUT)

2.150 -0.140 (-6.11%)
Delayed Quote Updated: 4:00 PM EST, Nov 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Nautilus Biotechnology, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
News headline image
Nautilus: 3 Key Takeaways for Long-Term Investors ↗
New oncology assays reached tau-level precision in one year instead of five, suggesting the core technology scales faster than expected. 
Via The Motley Fool
Topics Earnings
News headline image
Nautilus (NAUT) Q3 2026 Earnings Call Transcript ↗
Cash reserves extend runway into early 2028 as proteoform assay pipeline accelerates. 
Via The Motley Fool
Topics Earnings
News headline image
Nautilus Biotechnology Q3 Earnings Call Highlights ↗
Nautilus Biotechnology (NASDAQ:NAUT) reported third-quarter revenue of $200,000 as it continued its transition toward commercialization of its Voyager proteomics platform, with management reaffirming... 
Via MarketBeat
Topics Earnings
Nautilus Biotechnology (NASDAQ:NAUT) Q3 Earnings Beat and Pipeline Progress Drive Premarket Surge ↗
Via Chartmill
Topics Earnings
News headline image
Nautilus Biotechnology Reports Third Quarter 2026 Financial Results
From Nautilus Biotechnology Inc.
Via GlobeNewswire
News headline image
Nautilus to Measure Proteoforms Driving Alzheimer’s Disease and Cancer in ARPA-H-Funded SEEDS Consortium
Nautilus expects to receive up to $6 million to bring its Voyager™ Platform to a multidisciplinary team integrating protein science, AI, and computational modeling to develop new diagnostics and... 
From Nautilus Biotechnology Inc.
Via GlobeNewswire
News headline image
Nautilus Biotechnology to Announce Third Quarter 2026 Financial Results on October 27, 2026
From Nautilus Biotechnology Inc.
Via GlobeNewswire
These stocks are moving in today's session ↗
Via Chartmill
Let's have a look at the top gainers and losers in the middle of the day of today's session. ↗
Via Chartmill
These stocks have an unusual volume in today's session ↗
Via Chartmill
Curious about the stocks that are showing activity after the closing bell on Friday? ↗
Via Chartmill
Top movers analysis one hour before the close of the markets on 2026-09-29: top gainers and losers in today's session. ↗
Via Chartmill
These stocks are moving in today's session ↗
Via Chartmill
News headline image
Nature Methods Publication Reveals Deep Insights into Functional Biology through First-of-its-Kind Quantification of Tau Proteoforms
First large-scale, single-molecule analysis of the tau proteoform landscape reveals unique disease-associated modifications, a new source of potential biomarkers and drug targets, and a method Nautilus... 
From Nautilus Biotechnology Inc.
Via GlobeNewswire
These stocks are moving in today's session ↗
Via Chartmill
Top stock movements in today's session. ↗
Via Chartmill
Which stocks are gapping on Tuesday? ↗
Via Chartmill
News headline image
Nautilus Biotechnology Q2 Earnings Call Highlights ↗
Nautilus Biotechnology (NASDAQ:NAUT) said it is shifting a significant share of its research and development resources toward proteoform applications, citing customer interest and a delay in its... 
Via MarketBeat
Topics Earnings
News headline image
Nautilus Biotechnology Reports Second Quarter 2026 Financial Results
From Nautilus Biotechnology Inc.
Via GlobeNewswire
News headline image
Nautilus Biotechnology to Announce Second Quarter 2026 Financial Results on July 28, 2026
From Nautilus Biotechnology Inc.
Via GlobeNewswire
News headline image
Nautilus (NAUT) Q1 2026 Earnings Transcript ↗
Nautilus (NAUT) Q1 2026 Earnings Transcript 
Via The Motley Fool
News headline image
Nautilus Biotechnology Reports First Quarter 2026 Financial Results
From Nautilus Biotechnology Inc.
Via GlobeNewswire
News headline image
Forget Neuralink: The Real Brain Tech Trade Has 10 Names You’ve Never Heard ↗
The real brain computer interface opportunity isn’t in the headlines. These 10 stocks are building the systems that make it possible. 
Via InvestorPlace
Topics Artificial Intelligence Economy Initial Public Offering
News headline image
Nautilus Biotechnology to Announce First Quarter 2026 Financial Results on April 28, 2026
From Nautilus Biotechnology Inc.
Via GlobeNewswire
News headline image
Q1 Virtual Investor Summit Presentations Now Available On Demand
Via ACCESS Newswire
News headline image
Nautilus Biotechnology to Participate in the Investor Summit Group Virtual Conference
From Nautilus Biotechnology Inc.
Via GlobeNewswire
News headline image
Investor Summit Announces Q1 Presenter Line Up (Presentations 3/25, 1-on-1s 3/26)
Via ACCESS Newswire
News headline image
Nautilus Biotechnology Announces Baylor College of Medicine as First Early Access Program Customer for Voyager Platform
From Nautilus Biotechnology Inc.
Via GlobeNewswire
News headline image
Nautilus Biotechnology Appoints Proteomics Commercial Leader Amber Faust as Vice President of Sales
Veteran sales leader with proven proteomics and life sciences track record from Olink and SomaLogic joins Nautilus to accelerate commercial progress of its Voyager Platform 
From Nautilus Biotechnology Inc.
Via GlobeNewswire
News headline image
Nautilus (NAUT) Q4 2025 Earnings Call Transcript ↗
Nautilus (NAUT) Q4 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
< Previous 1 2 3 4 5 6 Next >